Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00506805
Recruitment Status : Completed
First Posted : July 25, 2007
Last Update Posted : May 28, 2012
Serenex, Inc.
Information provided by (Responsible Party):
Esanex Inc.

Brief Summary:
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Condition or disease Intervention/treatment Phase
Cancer Drug: SNX-5422 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma
Study Start Date : June 2007
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Single Arm Drug: SNX-5422
dose escalated, tablets every other day; undetermined duration until disease progression

Primary Outcome Measures :
  1. adverse events and other safety assessments [ Time Frame: continuous ]

Secondary Outcome Measures :
  1. tumor response measured by X-rays or scans [ Time Frame: after every 2 cycles ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >18 years old
  • histologically confirmed solid tumor malignancy
  • refractory to available therapy or for which no therapy is available
  • adequate organ function

Exclusion Criteria:

  • CNS malignancy
  • significant GI disease
  • at risk for prolonged QT interval

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00506805

United States, Arizona
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85258
United States, Tennessee
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Esanex Inc.
Serenex, Inc.
Study Director: Pfizer Call Center Pfizer

Additional Information:
Responsible Party: Esanex Inc. Identifier: NCT00506805     History of Changes
Other Study ID Numbers: B1311001
First Posted: July 25, 2007    Key Record Dates
Last Update Posted: May 28, 2012
Last Verified: May 2012

Keywords provided by Esanex Inc.:
solid tumor malignancy; Hsp90

Additional relevant MeSH terms: